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294 High requirement of pancreatic enzyme dose
M. Araujo1, M. Goyheneix1, C. Castan˜os1. 1Hospital Nacional de Pediatrı´a J. P.
Garrahan, Buenos Aires, Argentina
Pancreatic enzyme replacement therapy is essential for maintain adequate nutrition
in patients with cystic ﬁbrosis (CF) and steatorrhea. The different treatment
guidelines suggest dose of up to 10,000 lipase unit/kg/day, but in clinical practice
this dose is not sufﬁcient to correct steatorrhea for a group of patients.
Objective: To assess the requirement of pancreatic enzymes (PE) in a population
of CF patients and correlate with genetic mutation and others clinical parameters.
Patients and Methods: Crossover study of patients at the CF clinic in the period
Jun−Dec 2010. They are treated according to rules of CF patients. All patients with
PE dose greater than 10,000U/kg/d received inhibitors of proton pump. If patients
had steatorrhoea despite having reached the recommended dose of PE, we indicated
increase and regulate the dose according to the fatness of the meal. Were assessed
PE dose; height, weight and BMI z score (ZH, ZW and ZBMI), genetic mutation,
level of A&E vitamins.
Results: One hundred and ﬁve patients were assessed, 54 males, mean age 6.7 years,
with mean ZH −0.5, mean ZBMI −0.26. Median PE dose was 9,400U/kg/d
(range 2,000–48,000) and 50 patients received more than 10,000U/kg/d. 36% of
the patients were DF508 homozygote. These had higher requirements of PE
(16,600U/kg/d vs 9,300, P: 0.0015 T Test), had worse ZH (−0.93 vs −0.38, P: 0.02
T test) and ZW (−1.4 vs −0.6, P: 0.003). There were no signiﬁcant differences in
ZBMI, Van de Kamer and A & E vitamins. Nobody had ﬁbrosing colonopathy.
Conclusions: High requirement of PE dose was common in this population of pa-
tients with CF and this was correlated with severe genetic mutation. Complications
were no found.
295 Jejunal tube feeding for cystic ﬁbrosis-related gastroparesis: the
Nottingham experience
R.S. Chinuck1, J.C. Dewar2. 1Nottingham University Hospitals, City Campus,
Dietetics and Nutrition, Nottingham, United Kingdom; 2Nottingham University
Hospitals, City Campus, Respiratory Medicine, Nottingham, United Kingdom
Introduction: Gastroparesis occurs predominantly in children, advanced lung
disease and post lung transplantation [1,2]. Current therapies include prokinetic
medications or dietary manipulation [1,2]. However its prevalence, treatments and
impact on clinical condition remain un-determined.
Objective: To present the Nottingham experience of jejunal placement as a
treatment for cystic ﬁbrosis (CF)-related Gastroparesis.
Method: 2 females, 1 male, 42, 36 and 21 years respectively, with Gastroparesis,
failed to respond to domperidone, erythromycin, and were unable to maintain
nutrition by NG feeding. Jejunal tube feed (accompanied by fasting for 3 months
by one patient) was undertaken.
Results: Nasojejunal tube feeding resulted in signiﬁcant resolution of symptoms,
recurring with return to NG feeding and eating. Hence, all three agreed to surgical
jejunostomy. All patients experienced signiﬁcant negative body image as a result.
However, signiﬁcant improvements in clinical condition were seen, with stabilisation
or increase in BMI, and lung function.
Discussion: Whilst surgical jejunostomy has enhanced nutrition and clinical status
in our patient group, it resulted in signiﬁcant psychological issues. The interdis-
ciplinary working necessitated, and new skills required to manage jejunostomies,
poses considerable challenges to the CFMDT.
Conclusion: Jejunal tube feeding coupled with a sustained period of 3 months
of no oral diet may be a newly emerging, long-term treatment for CF-related
Gastroparesis.
Reference(s)
[1] Tonelli AR et al. J Cystic Fibrosis 2009 May; 8(3): 193−7.
[2] Bodet-Miln C et al. J Heart Lung Transplant 2006 Sep; 25(9): 1077−83.
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The appetite stimulant, megestrol acetate (Megace) has been used in patients with
decreased appetite and poor weight gain; we performed a retrospective evaluation
of Megace in our two cystic ﬁbrosis (CF) centers (Caen and Lisieux), in patients
non responsive to conventional hypercaloric diets as an alternative to gastrostomy.
Methods: We identiﬁed all patients treated with Megace from January 2007 to
January 2010 and we evaluated: quality of life, weight, lung function, cortisol level
and side effects.
Results: 6 patients (17 to 33 years) were included in the evaluation; the aver-
age initial dose was 6.0mg/kg/day (2.5−8.0mg/kg/day) and the ﬁnal dose was
3.8mg/kg/day (1.5−7.0mg/kg/day); the mean duration of therapy was 18.5 months
(4.0 to 32.0 months); 6 patients were on therapy for more than one year and one
for less than one year; all patients experienced an improvment in their quality of
life (appetite, fatigue, respiratory comfort); the average weight gain was 5.6 kg
(1.5 to 8.0 kg); the average pre Megace FVC was 49.5% predicted and post
Megace 51.5% predicted; the side effects were: hematocolpos, transitory adrenal
insufﬁciency.
Conclusion: The use of Megace was associated with an improvement of nutritional
status and lung function; to standardize the use of Megace we suggest to use
a starting dose of 5.0mg/kg/day; if weight gain is under 2%, increment to
7.5mg/kg/day for a maximal duration of 9 months; cortisol and adrenal function
has to be routinely evaluated every six months.
298 Vitamin deﬁciency in children with cystic ﬁbrosis
A.M. Olesen1, P.O. Schiøtz1, H.V. Olesen1. 1Aarhus University Hospital Skejby,
Cystic Fibrosis Center Skejby, Arhus, Denmark
Objectives: According to European consensus, we recommend vitamin supplements
to all cystic ﬁbrosis (CF) patients. For two years, while prescribing AquADEKs
liquid and softgels in the recommended doses, we measured the plasma levels of
A, D and E vitamins in all patients, in order to asses the status in paediatric and
adult CF patients at our center.
Methods: Plasma levels were obtained at annual assesment. Deﬁciency was
described as below lower level of normal local values (vit D 50 nmol/l; vit A
0.7mmol/l for <7 y, 0.91 for 7 y; vit E 17 mmol/l). In case of deﬁciency the cause
was discussed with patients. For 1/3 of the patients a second sample was obtained
3−12 months later.
Results: The results for the 83 paediatric patients are listed in the table. 7 patients
were deﬁcient of all vitamins (12−17 y). 31 patients had a second test. For vitamin D
4 of 8 patients with low levels were now normal. For vitamin A 9 of 13 with
deﬁciency were corrected. For vitamin E 10 of 19 patients were reversed to normal.
The results for the adults will be presented at the conference.
Agegroup 0−5 years
(n = 22)
6−11 years
(n = 27)
12−17 years
(n = 34)
Vit D deﬁciency 0 (0%)* 0 (0%)* 16 (47%)*
Vit A deﬁciency 1 (5%) 10 (39%) 13 (39%)
Vit E deﬁciency 4 (18%) 9 (35%) 21 (64%)
*With a limit of 75 nmol/l the numbers were 3(14%); 13(48%); 27(79%).
Conclusion: We found a high number of patients with fat-soluble vitamin deﬁ-
ciency, despite prescription of relevant vitamin supplementation. The taste of the
vitamins was a signiﬁcant barrier to compliance, the principal cause of deﬁciency.
Deﬁciency was especially prominent in teenagers. Guidance leading to improved
compliance corrected most deﬁciencies.
